繁體版 / 簡體版
 
R&D PORTFOLIO
/ MB-110

MB-110

Indication
Hepatitis C
Product Advantages
superior inhibition capacity against prevalent HCV genotypes in Asia (1b, 2a and 3a)
Status
Obtained the investigational new drug (IND) approval from FDA for human clinical trial
Mechanism
Small molecule, highly active and selective inhibitor of NS5A protein of hepatitis C virus (HCV)
Potential Market
According to the statistics of the World Health Organization, about 700,000 people die of liver diseases related to hepatitis C every year. By 2015, the global market has reached 24 billion U.S. dollars. According to the IMS data, the global anti-hepatitis C drug will reach 36 billion U.S. dollars by 2020

Pre-clinical results

MB-110(NSFAI003, DBPR110) has better bioavailability and longer half-life
Good biological stability
 

Mechanism


好玩棋牌 湖北11选五遗漏直选3 安徽11选5走势图今天 重庆福彩幸运农场玩法 黑十一选五走势图 3d试机号走势图带连线500期 北京快中彩开奖 炒股有风险吗 福建十一选五前三走势图 陕西快乐十分今天开奖表 湖北共享快三